Abstract
Large genome-mapping consortia and thousands of genome-wide association studies have identified non-protein-coding elements in the genome as having a central role in various biological processes. However, decoding the functions of the millions of putative regulatory elements discovered in these studies remains challenging. CRISPR–Cas9-based epigenome editing technologies have enabled precise perturbation of the activity of specific regulatory elements. Here we describe CRISPR–Cas9-based epigenomic regulatory element screening (CERES) for improved high-throughput screening of regulatory element activity in the native genomic context. Using dCas9KRAB repressor and dCas9p300 activator constructs and lentiviral single guide RNA libraries to target DNase I hypersensitive sites surrounding a gene of interest, we carried out both loss- and gain-of-function screens to identify regulatory elements for the β-globin and HER2 loci in human cells. CERES readily identified known and previously unidentified regulatory elements, some of which were dependent on cell type or direction of perturbation. This technology allows the high-throughput functional annotation of putative regulatory elements in their native chromosomal context.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Temporal chromatin accessibility changes define transcriptional states essential for osteosarcoma metastasis
Nature Communications Open Access 08 November 2023
-
CRISPR/Cas9 technology: applications in oocytes and early embryos
Journal of Translational Medicine Open Access 24 October 2023
-
ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma
Nature Communications Open Access 07 April 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout






Accession codes
References
Thurman, R.E. et al. The accessible chromatin landscape of the human genome. Nature 489, 75–82 (2012).
Hindorff, L.A., Junkins, H.A., Mehta, J.P. & Manolio, T.A. A Catalog of Published Genome-Wide Association Studies. http://www.genome.gov/gwastudies (2009).
ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
Bernstein, B.E. et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat. Biotechnol. 28, 1045–1048 (2010).
Arnold, C.D. et al. Genome-wide quantitative enhancer activity maps identified by STARR-seq. Science 339, 1074–1077 (2013).
Vockley, C.M. et al. Massively parallel quantification of the regulatory effects of noncoding genetic variation in a human cohort. Genome Res. 25, 1206–1214 (2015).
Vockley, C.M. et al. Direct GR binding sites potentiate clusters of TF binding across the human genome. Cell 166, 1269–1281 (2016).
Barrangou, R. & Doudna, J.A. Applications of CRISPR technologies in research and beyond. Nat. Biotechnol. 34, 933–941 (2016).
Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).
Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
Cho, S.W., Kim, S., Kim, J.M. & Kim, J.-S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230–232 (2013).
Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87 (2014).
Wang, T., Wei, J.J., Sabatini, D.M. & Lander, E.S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80–84 (2014).
Koike-Yusa, H., Li, Y., Tan, E.P., Del Castillo Velasco-Herrera, M. & Yusa, K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32, 267–273 (2014).
Canver, M.C. et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527, 192–197 (2015).
Korkmaz, G. et al. Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. Nat. Biotechnol. 34, 192–198 (2016).
Rajagopal, N. et al. High-throughput mapping of regulatory DNA. Nat. Biotechnol. 34, 167–174 (2016).
Diao, Y. et al. A new class of temporarily phenotypic enhancers identified by CRISPR/Cas9-mediated genetic screening. Genome Res. 26, 397–405 (2016).
Sanjana, N.E. et al. High-resolution interrogation of functional elements in the noncoding genome. Science 353, 1545–1549 (2016).
Vierstra, J. et al. Functional footprinting of regulatory DNA. Nat. Methods 12, 927–930 (2015).
Housden, B.E. et al. Loss-of-function genetic tools for animal models: cross-species and cross-platform differences. Nat. Rev. Genet. 18, 24–40 (2017).
Thakore, P.I., Black, J.B., Hilton, I.B. & Gersbach, C.A. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat. Methods 13, 127–137 (2016).
Qi, L.S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).
Gilbert, L.A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451 (2013).
Gao, X. et al. Reprogramming to pluripotency using designer TALE transcription factors targeting enhancers. Stem Cell Reports 1, 183–197 (2013).
Gao, X. et al. Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. Nucleic Acids Res. 42, e155 (2014).
Gilbert, L.A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647–661 (2014).
Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583–588 (2015).
Hilton, I.B. et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat. Biotechnol. 33, 510–517 (2015).
Kearns, N.A. et al. Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat. Methods 12, 401–403 (2015).
Thakore, P.I. et al. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat. Methods 12, 1143–1149 (2015).
Xu, X. et al. A CRISPR-based approach for targeted DNA demethylation. Cell Discov. 2, 16009 (2016).
Choudhury, S.R., Cui, Y., Lubecka, K., Stefanska, B. & Irudayaraj, J. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. Oncotarget 7, 46545–46556 (2016).
Vojta, A. et al. Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res. 44, 5615–5628 (2016).
Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833–838 (2013).
Liu, X.S. et al. Editing DNA methylation in the mammalian genome. Cell 167, 233–247 (2016).
Boyle, A.P. et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 132, 311–322 (2008).
Sabo, P.J. et al. Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays. Nat. Methods 3, 511–518 (2006).
Hardison, R. et al. Locus control regions of mammalian β-globin gene clusters: combining phylogenetic analyses and experimental results to gain functional insights. Gene 205, 73–94 (1997).
Baron, M.H. Developmental regulation of the vertebrate globin multigene family. Gene Expr. 6, 129–137 (1996).
Dean, A., Ley, T.J., Humphries, R.K., Fordis, M. & Schechter, A.N. Inducible transcription of five globin genes in K562 human leukemia cells. Proc. Natl. Acad. Sci. USA 80, 5515–5519 (1983).
Song, L. et al. Open chromatin defined by DNaseI and FAIRE identifies regulatory elements that shape cell-type identity. Genome Res. 21, 1757–1767 (2011).
Vu, T. & Claret, F.X. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2, 62 (2012).
Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
Gajria, D. & Chandarlapaty, S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev. Anticancer Ther. 11, 263–275 (2011).
Hurtado, A. et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456, 663–666 (2008).
Chu, P.-Y., Li, T.-K., Ding, S.-T., Lai, I.R. & Shen, T.-L. EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells. J. Biol. Chem. 285, 29279–29285 (2010).
Fulco, C.P. et al. Systematic mapping of functional enhancer-promoter connections with CRISPR interference. Science 354, 769–773 (2016).
Findlay, G.M., Boyle, E.A., Hause, R.J., Klein, J.C. & Shendure, J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 513, 120–123 (2014).
Sanjana, N.E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
Song, L. & Crawford, G.E. DNase-seq: a high-resolution technique for mapping active gene regulatory elements across the genome from mammalian cells. Cold Spring Harb. Protoc. 2010, pdb.prot5384 (2010).
O'Brien, A. & Bailey, T.L. GT-Scan: identifying unique genomic targets. Bioinformatics 30, 2673–2675 (2014).
Salmon, P. & Trono, D. Production and titration of lentiviral vectors. Curr. Protoc. Neurosci. Chapter 4, Unit 4.21 (2006).
Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Acknowledgements
This work was supported by the Thorek Memorial Foundation, the US National Institutes of Health (NIH) (grants R01DA036865, R41GM119914, and U01HG007900 to G.E.C., T.E.R., and C.A.G.; core facility grant P30AR066527; Biotechnology Training Grant T32GM008555 to T.S.K. and J.B.B.; Director's New Innovator Award DP2OD008586 to C.A.G.), and the National Science Foundation (NSF) (Faculty Early Career Development (CAREER) Award CBET-1151035 to C.A.G.).
Author information
Authors and Affiliations
Contributions
T.S.K., G.E.C., T.E.R., and C.A.G. designed experiments. T.S.K., J.B.B., A.S., L.S., and M.C. performed the experiments. I.B.H. provided critical reagents. T.S.K., G.E.C., T.E.R., and C.A.G. analyzed the data. T.S.K. and C.A.G. wrote the manuscript, with contributions by all others authors.
Corresponding authors
Ethics declarations
Competing interests
T.S.K., J.B.B., I.B.H., G.E.C., T.E.R., and C.A.G. are named inventors on patent applications related to genome engineering. T.S.K., G.E.C., T.E.R., and C.A.G. are founders of Element Genomics.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–16 and Supplementary Tables 1–7 (PDF 4173 kb)
Rights and permissions
About this article
Cite this article
Klann, T., Black, J., Chellappan, M. et al. CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nat Biotechnol 35, 561–568 (2017). https://doi.org/10.1038/nbt.3853
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3853
This article is cited by
-
CRISPR/Cas9 technology: applications in oocytes and early embryos
Journal of Translational Medicine (2023)
-
Temporal chromatin accessibility changes define transcriptional states essential for osteosarcoma metastasis
Nature Communications (2023)
-
Identification of non-coding silencer elements and their regulation of gene expression
Nature Reviews Molecular Cell Biology (2023)
-
Dynamic network-guided CRISPRi screen identifies CTCF-loop-constrained nonlinear enhancer gene regulatory activity during cell state transitions
Nature Genetics (2023)
-
ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma
Nature Communications (2023)